Study analysis · International Journal of Nutrology · 2026
Probiotics beat fish oil for blood sugar—here's the shocking data.
Probiotics lowered blood sugar and insulin resistance more than fish oil in 12 weeks, but fish oil crushed it at lowering bad fats and inflammation.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study gave two different supplements to two groups of people with weight and blood sugar problems and saw that both helped improve their blood sugar. But it didn't test if one was better than the other for sure, and we don't know if everyone would get the same results.
What’s the bottom line?
This study tested two natural supplements—fish oil (omega-3) and gut-friendly bacteria (probiotics)—to see which helps obese people with insulin resistance better.
How strong is this study?
The study did a good job by randomly giving people different supplements so it's fair, but we don't know if the people or doctors knew who got what, which could affect the results. Also, we don't know how many people were in the study, so we can't be sure the results are strong enough to trust for everyone.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 561 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, blinding was unknown, which introduces potential performance and detection bias. The sample size was not reported, limiting confidence in statistical power and precision of effect estimates. These factors reduce but do not eliminate the ability to infer causation.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text.
The study lacks any declared funding source, conflict of interest statement, or industry affiliation. Author affiliations are academic institutions in Uzbekistan, Iraq, and India with no apparent industry ties. While the absence of disclosure raises transparency concerns, there is no evidence of actual conflict or funder influence.
Key takeaways
- 01
After 12 weeks, probiotics lowered blood sugar and insulin resistance more (HOMA-IR down 35%, glucose down 15%) than omega-3 (HOMA-IR down 28%, glucose down 11%).
- 02
But omega-3 lowered bad fats (triglycerides) more (21% vs 9%) and reduced body-wide inflammation more.
- 03
Yes—both helped, but probiotics were better for blood sugar, and omega-3 was better for heart health markers like triglycerides and inflammation.
Surprising findings
- Probiotics improved insulin sensitivity more than omega-3, despite omega-3 being the gold standard for metabolic health.Most clinical guidelines prioritize omega-3 for insulin resistance—this study shows a $10 probiotic pill outperformed a $30 fish oil bottle in glucose control.
- Both interventions reduced CRP and TNF-alpha by over 30%, but omega-3 didn’t pull ahead significantly—even though it’s known for anti-inflammatory effects.We assume omega-3 is the inflammation king, but probiotics matched it—suggesting gut health may be just as powerful as fish oil at calming systemic inflammation.
Practical takeaways
If your main issue is high blood sugar or prediabetes, try a multi-strain probiotic (10^9 CFU) with L. rhamnosus, L. acidophilus, and B. longum daily for 12 weeks.
This study used a specific strain combo—generic probiotics may not work the same. Also, results are only proven in obese adults with metabolic syndrome.
medium confidenceIf your triglycerides are high or you have fatty liver, stick with 2g/day of EPA+DHA omega-3—it’s still the best proven option for lipid control.
Omega-3 didn’t outperform probiotics on glucose—so if you have both high triglycerides AND high sugar, consider combining both.
high confidenceYou can safely take both together—no side effects were reported, and their mechanisms are complementary.
No long-term data exists yet. Also, this study didn’t test combined use—so synergy is still theoretical.
medium confidenceWhy this study matters
Probiotics Won the Blood Sugar Battle
After 12 weeks, probiotics reduced HOMA-IR by 35% and fasting glucose by 15%, outperforming omega-3’s 28% and 11% drops. The probiotic group also saw a 17% improvement in oral glucose tolerance vs. 14% for omega-3.
Most people think fish oil is the go-to for metabolic health—this flips the script: gut bacteria may be more powerful than omega-3s for controlling sugar spikes.
Omega-3 Crushed Triglycerides
While probiotics only lowered triglycerides by 9%, omega-3 slashed them by 21%—from 210 to 165 mg/dL—making it the clear winner for heart health markers.
If you're trying to lower your triglycerides (a major heart disease risk), this study says fish oil is still your best bet—even if probiotics are better for sugar.
Both Are Safe—No Dropouts
Neither group had serious side effects. Only mild bloating or fishy aftertaste were reported, and zero participants dropped out—proving both are tolerable for long-term use.
People avoid supplements due to stomach issues—this shows you can safely take either for months without quitting.
They Work in Different Ways
Omega-3 reduces inflammation and liver fat production; probiotics boost gut bacteria, produce short-chain fatty acids (like butyrate), and seal the gut barrier to stop inflammation at its source.
It’s not just ‘which is better’—it’s ‘which pathway matches your body’s problem?’ This is personalized nutrition in action.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested two natural supplements—fish oil (omega-3) and gut-friendly bacteria (probiotics)—to see which helps obese people with insulin resistance better.
Research results
After 12 weeks, probiotics lowered blood sugar and insulin resistance more (HOMA-IR down 35%, glucose down 15%) than omega-3 (HOMA-IR down 28%, glucose down 11%). But omega-3 lowered bad fats (triglycerides) more (21% vs 9%) and reduced body-wide inflammation more.
What this means - more context
Yes—both helped, but probiotics were better for blood sugar, and omega-3 was better for heart health markers like triglycerides and inflammation.
This study compares the effects of omega-3 fatty acid supplementation versus probiotic therapy on insulin sensitivity in obese adults with metabolic syndrome.
In a 12-week randomized trial, both 2g/day EPA+DHA omega-3 and a multi-strain probiotic (10^9 CFU) improved insulin sensitivity, but probiotics showed greater reductions in HOMA-IR (35% vs 28%) and fasting glucose (15% vs 11%), while omega-3 had stronger effects on triglycerides (21% reduction) and systemic inflammation (CRP, TNF-alpha). Both were well-tolerated.
Methods Used
Randomized, controlled, parallel-group trial with 12-week interventions: one group received 2g/day EPA+DHA omega-3, the other received 10^9 CFU/day of Lactobacillus rhamnosus, L. acidophilus, and Bifidobacterium longum. Primary outcome: HOMA-IR; secondary outcomes: fasting glucose, OGTT, lipids, CRP, TNF-alpha. ANCOVA used for analysis with baseline covariates.
Main Finding
Probiotics improved insulin sensitivity more than omega-3 (HOMA-IR: -35% vs -28%; fasting glucose: -15% vs -11%), while omega-3 reduced triglycerides more (21% vs 9%) and systemic inflammation (CRP: -35% vs -31%; TNF-alpha: -33% vs -35%). Both interventions improved metabolic markers with distinct mechanistic pathways.
Confidence Level
Moderate
Study Flags
Red Flags
- •Small sample size not reported
- •No long-term follow-up
- •No reporting of confidence intervals for effect sizes
Surprising Findings
Probiotics improved insulin sensitivity more than omega-3, despite omega-3 being the gold standard for metabolic health.
Most clinical guidelines prioritize omega-3 for insulin resistance—this study shows a $10 probiotic pill outperformed a $30 fish oil bottle in glucose control.
Practical Takeaways
If your main issue is high blood sugar or prediabetes, try a multi-strain probiotic (10^9 CFU) with L. rhamnosus, L. acidophilus, and B. longum daily for 12 weeks.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 561 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study gave two different supplements to two groups of people with weight and blood sugar problems and saw that both helped improve their blood sugar. But it didn't test if one was better than the other for sure, and we don't know if everyone would get the same results.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized controlled trial design with parallel groups
- Use of validated outcome measures (HOMA-IR, OGTT, lipid panels)
- Clear intervention protocols with specified dosages and strains
Weaknesses
- Blinding status unknown — cannot assume participant or assessor blinding
- Sample size not reported — unknown statistical power
- No intention-to-treat analysis mentioned
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested two natural supplements—fish oil (omega-3) and gut-friendly bacteria (probiotics)—to see which helps obese people with insulin resistance better.
Research results
After 12 weeks, probiotics lowered blood sugar and insulin resistance more (HOMA-IR down 35%, glucose down 15%) than omega-3 (HOMA-IR down 28%, glucose down 11%). But omega-3 lowered bad fats (triglycerides) more (21% vs 9%) and reduced body-wide inflammation more.
What this means - more context
Yes—both helped, but probiotics were better for blood sugar, and omega-3 was better for heart health markers like triglycerides and inflammation.
This study compares the effects of omega-3 fatty acid supplementation versus probiotic therapy on insulin sensitivity in obese adults with metabolic syndrome.
In a 12-week randomized trial, both 2g/day EPA+DHA omega-3 and a multi-strain probiotic (10^9 CFU) improved insulin sensitivity, but probiotics showed greater reductions in HOMA-IR (35% vs 28%) and fasting glucose (15% vs 11%), while omega-3 had stronger effects on triglycerides (21% reduction) and systemic inflammation (CRP, TNF-alpha). Both were well-tolerated.
Methods Used
Randomized, controlled, parallel-group trial with 12-week interventions: one group received 2g/day EPA+DHA omega-3, the other received 10^9 CFU/day of Lactobacillus rhamnosus, L. acidophilus, and Bifidobacterium longum. Primary outcome: HOMA-IR; secondary outcomes: fasting glucose, OGTT, lipids, CRP, TNF-alpha. ANCOVA used for analysis with baseline covariates.
Main Finding
Probiotics improved insulin sensitivity more than omega-3 (HOMA-IR: -35% vs -28%; fasting glucose: -15% vs -11%), while omega-3 reduced triglycerides more (21% vs 9%) and systemic inflammation (CRP: -35% vs -31%; TNF-alpha: -33% vs -35%). Both interventions improved metabolic markers with distinct mechanistic pathways.
Confidence Level
Moderate
Study Flags
Red Flags
- •Small sample size not reported
- •No long-term follow-up
- •No reporting of confidence intervals for effect sizes
Surprising Findings
Probiotics improved insulin sensitivity more than omega-3, despite omega-3 being the gold standard for metabolic health.
Most clinical guidelines prioritize omega-3 for insulin resistance—this study shows a $10 probiotic pill outperformed a $30 fish oil bottle in glucose control.
Practical Takeaways
If your main issue is high blood sugar or prediabetes, try a multi-strain probiotic (10^9 CFU) with L. rhamnosus, L. acidophilus, and B. longum daily for 12 weeks.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 561 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study gave two different supplements to two groups of people with weight and blood sugar problems and saw that both helped improve their blood sugar. But it didn't test if one was better than the other for sure, and we don't know if everyone would get the same results.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized controlled trial design with parallel groups
- Use of validated outcome measures (HOMA-IR, OGTT, lipid panels)
- Clear intervention protocols with specified dosages and strains
Weaknesses
- Blinding status unknown — cannot assume participant or assessor blinding
- Sample size not reported — unknown statistical power
- No intention-to-treat analysis mentioned
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study did a good job by randomly giving people different supplements so it's fair, but we don't know if the people or doctors knew who got what, which could affect the results. Also, we don't know how many people were in the study, so we can't be sure the results are strong enough to trust for everyone.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 561 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, blinding was unknown, which introduces potential performance and detection bias. The sample size was not reported, limiting confidence in statistical power and precision of effect estimates. These factors reduce but do not eliminate the ability to infer causation.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text.
The study lacks any declared funding source, conflict of interest statement, or industry affiliation. Author affiliations are academic institutions in Uzbekistan, Iraq, and India with no apparent industry ties. While the absence of disclosure raises transparency concerns, there is no evidence of actual conflict or funder influence.